quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·17d
PRRelease
Neurocrine Biosciences Inc. logo
Soleno Therapeutics Inc. logo

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

NBIX· Neurocrine Biosciences Inc.SLNO· Soleno Therapeutics Inc.
Health Care
Original source

Companies

  • NBIX
    Neurocrine Biosciences Inc.
    Health Care
  • SLNO
    Soleno Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 24NBIXUpdateWolfe Research$160.00
  • Jan 8NBIXUpdateMorgan Stanley$175.00
  • Nov 18SLNOUpdateWolfe Research$75.00
  • Oct 21NBIXUpdateCitigroup$175.00
  • Oct 7SLNOUpdateGoldman$125.00
  • Aug 20SLNOUpdateWells Fargo$123.00

Related

  • PR1d
    Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
  • SEC3d
    SEC Form SC 14D9 filed by Soleno Therapeutics Inc.
  • SEC3d
    SEC Form SC TO-T filed by Soleno Therapeutics Inc.
  • SEC8d
    SEC Form DEFA14A filed by Neurocrine Biosciences Inc.
  • SEC8d
    SEC Form DEF 14A filed by Neurocrine Biosciences Inc.
  • PR8d
    Folia Health Launches "BRAVE-PWS" Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
  • PR9d
    Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
  • PR9d
    Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022